CIC
VKTX icon

Chase Investment Counsel’s Viking Therapeutics VKTX Stock Holding History

Chase Investment Counsel’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,702
Closed -$221K – 149
2024
Q1 		$221K Buy
+2,702
New +$120K 0.08% 131

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chase Investment Counsel's VKTX Position: Q2 2024 in Review

Chase Investment Counsel sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 2,702 shares — an estimated $221K sold.

Chase Investment Counsel first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $221K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Chase Investment Counsel reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 2,702 Viking Therapeutics shares in Q2 2024, an estimated $221K.
  • Chase Investment Counsel first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
  • Chase Investment Counsel's Viking Therapeutics position peaked at $221K in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Chase Investment Counsel's 13F filing for Q2 2024, filed 2 Aug 2024.